Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 1, keine Gesamtzahl für „Iressa“
Suchtreffer
Begriffe & Kennungen
Gefitinib
Eintrag öffnenIressa
Eintrag öffnenIressa · 4.1 Therapeutic indications · 1
Eintrag öffnenIressa · 4.3 Contraindications · 1
Eintrag öffnenIressa · 4.3 · Breast-feeding (see section 4.6).
Eintrag öffnenIressa · 4.3 · Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
Eintrag öffnenIressa · 4.4 Special warnings and precautions for use · 1
Eintrag öffnenIressa · 4.5 Interaction with other medicinal products and other forms of interaction · 1
Eintrag öffnenIressa · 4.5 · Active substances that may have their plasma concentrations altered by gefitinib In vitro studies have shown t
Eintrag öffnenIressa · 4.5 · Active substances that may increase gefitinib plasma concentrations In vitro studies have shown that gefitinib
Eintrag öffnenIressa · 4.5 · Active substances that may reduce gefitinib plasma concentrations Substances that are inducers of CYP3A4 activ
Eintrag öffnenIressa · 4.5 · Gefitinib inhibits the transporter protein BCRP in vitro, but the clinical relevance of this finding is unknow
Eintrag öffnenIressa · 4.5 · Other potential interactions INR elevations and/or bleeding events have been reported in some patients concomi
Eintrag öffnenIressa · 4.5 · Substances that cause significant sustained elevation in gastric pH may reduce gefitinib plasma concentrations
Eintrag öffnenIressa · 4.5 · The metabolism of gefitinib is via the cytochrome P450 isoenzyme CYP3A4 (predominantly) and via CYP2D6.
Eintrag öffnenIressa · 4.5 · There are no data on concomitant treatment with an inhibitor of CYP2D6 but potent inhibitors of this enzyme mi
Eintrag öffnenIressa · 4.6 Fertility, pregnancy and lactation · 1
Eintrag öffnenIressa · 4.8 Undesirable effects · 1
Eintrag öffnenIressa · 4.8 · Frequencies of occurrence of undesirable effects are defined as: very common (≥ 1/10); common (≥ 1/100 to < 1/
Eintrag öffnenIressa · 4.8 · In a phase III open-label clinical trial (IPASS) in 1217 patients comparing IRESSA to carboplatin/paclitaxel d
Eintrag öffnen